Jordyn Sava is an editor for Targeted Oncology.
ONA-XR and Anastrozole Signals Early Clinical Activity in HR+ Endometrial Cancer
February 7th 2023Early findings from the phase 2 OATH trial show treatment with ONA-XR plus anastrozole elicits a 4-month progression- free survival rate of 77% and overall response rate of 22% in patients with HR-positive metastatic endometrial cancer.
UPGRADE-A Trial of Upifitamab Rilsodotin in Ovarian Cancer Begins Expansion Phase
February 7th 2023The UPGRADE-A trial assessing the combination of upifitamab rilsodotin and carboplatin in patients with platinum-sensitive high-grade serous ovarian cancer has initiated the dose-expansion portion of the study.
Accelerated Dosing of Ropeginterferon Alfa-2b May Improve Responses in PV
February 6th 2023The dose and titration of ropeginterferon alfa-2b is safe and effective for patients with polycythemia vera. However, additional studies are needed to provide rationale for an amended, higher initial dosage, and rapid titration.
Precision Oncology Database Highlights Racial/Ethnic Disparities Across Cancer Types
February 6th 2023While project GENIE provides public access to the representation of cancer distribution among racial and ethnic minorities, findings suggest its data does not reflect the true landscape of patients with cancer and may misrepresent the disease burden across patient populations.
Marginal PFS Difference With Autologous HSCT and KCd Consolidation in Multiple Myeloma
February 3rd 2023Based on findings from the phase 2 CARDAMON studies, further research is needed to explore deferred autologous hematopoietic stem-cell transplantation in some subgroups of patients with multiple myeloma.
Phase 3 Trial of Pembrolizumab Meets Primary PFS End Point in Endometrial Cancer
February 3rd 2023The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.
Beckermann on Recent Data and Hopes for the Evolving RCC Landscape
February 2nd 2023In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.
FDA Receives BLA Resubmission of Remestemcel-L for Pediatric SR-aGVHD
February 2nd 2023As requested by the FDA, a new biologics license application including updated scientific rationale has been submitted for remestemcel-L as treatment for patients with steroid-refractory acute graft-vs-host disease.
SBRT Plus Sorafenib Improves Survival in Locally Advanced HCC
February 1st 2023In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.
START-001 Study of STAR0602 Doses First Patient With PD-1 Refractory Solid Tumors
January 31st 2023The START-001 trial will administer STAR0602 to patients with PD-1 refractory advanced solid tumors in order to evaluate the safety, tolerability, and preliminary clinical activity of the agent as a monotherapy.
Follow-Up of Lenvatinib/Pembrolizumab Elicits Efficacy in Endometrial Cancer
January 30th 2023According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.
China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS Metastases
January 30th 2023The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.
FDA Okays Guardant360 Test as CDx for Elacestrant in ESR1-mutated Breast Cancer
January 30th 2023The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.